VLADISLAV YEGANOV: Open Payments
NPI 1538145792 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,524 in 183 payments from 17 companies in 2025. Trend: 2023 $2,828 · 2024 $3,404 · 2025 $3,524
Food & beverage: $3,524
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 43 | $966 |
| Axsome Therapeutics, Inc. | 25 | $398 |
| Teva Pharmaceuticals USA, Inc. | 14 | $329 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $259 |
| Vanda Pharmaceuticals Inc. | 11 | $256 |
| Janssen Pharmaceuticals, Inc | 12 | $231 |
| E.R. Squibb & Sons, L.L.C. | 12 | $189 |
| Alkermes, Inc. | 9 | $179 |
| Avadel CNS Pharmaceuticals, LLC | 10 | $170 |
| Corium, LLC | 10 | $167 |
Products named: INGREZZA, AUSTEDO XR, Sunosi, CAPLYTA, FANAPT, INVEGA SUSTENNA, COBENFY, ARISTADA.
Industry payments across TX — which companies pay providers there.
